Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease
<p>Abstract</p> <p>Background</p> <p>Intravenous immunoglobulin (IVIg) treatment results in an effective response from patients with acute-phase Kawasaki disease (KD), but 16.5% of them remain nonresponsive to IVIg. To address this therapeutic challenge, we tried a new...
Main Authors: | Ohno Naohito, Nagi-Miura Noriko, Yamada Hitomi, Yokouchi Yuki, Nagao Tomokazu, Oharaseki Toshiaki, Takahashi Kei, Saji Tsutomu, Okazaki Tomio, Suzuki Kazuo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | Pediatric Rheumatology Online Journal |
Subjects: | |
Online Access: | http://www.ped-rheum.com/content/9/1/30 |
Similar Items
-
Beneficial effects of anti-apolipoprotein A-2 on an animal model for coronary arteritis in Kawasaki disease
by: Fuyu Ito, et al.
Published: (2022-12-01) -
Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial
by: Keiji Hirai, et al.
Published: (2017-06-01) -
Acute renal failure after kidney transplantation due to mizoribine-induced ureteral stones
by: Mao Ding, et al.
Published: (2024-01-01) -
In Vitro and in Vivo Antiviral Activity of Mizoribine Against Foot-And-Mouth Disease Virus
by: Shi-Fang Li, et al.
Published: (2019-05-01) -
Kawasaki Disease: An Update on Diagnosis and Treatment
by: Ho-Chang Kuo, et al.
Published: (2012-02-01)